First clinical data for BioMarin hemo A gene therapy

At its R&D day on Wednesday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported preliminary data from the first eight patients with severe hemophilia A who received a single dose of IV BMN 270 in an ongoing dose-escalation Phase I/II

Read the full 377 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE